Home » Stocks » Soligenix

Soligenix, Inc. (SNGX)

Stock Price: $2.13 USD -0.04 (-1.62%)
Updated Aug 12, 2020 11:48 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 61.54M
Revenue (ttm) 4.41M
Net Income (ttm) -15.30M
Shares Out 28.96M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $2.13
Previous Close $2.16
Change ($) -0.04
Change (%) -1.62%
Day's Open 2.17
Day's Range 2.04 - 2.22
Day's Volume 492,112
52-Week Range 0.85 - 3.54

More Stats

Market Cap 61.54M
Enterprise Value 54.43M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 28.96M
Float 26.48M
EPS (basic) -0.72
EPS (diluted) -0.74
FCF / Share -0.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 327,250
Short Ratio 0.29
Short % of Float 2.28%
Beta 1.36
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 13.96
PB Ratio 18.62
Revenue 4.41M
Operating Income -16.71M
Net Income -15.30M
Free Cash Flow -7.94M
Net Cash 7.11M
Net Cash / Share 0.25
Gross Margin 24.09%
Operating Margin -379.05%
Profit Margin -346.90%
FCF Margin -180.13%
ROA -107.87%
ROE -347.82%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.42*
(108.00% upside)
Low
2.00
Current: $2.13
High
7.25
Target: 4.42
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue4.635.245.4310.458.777.043.223.147.661.95
Revenue Growth-11.67%-3.52%-48.01%19.16%24.5%118.45%2.53%-58.96%293.44%-
Gross Profit1.060.641.122.021.891.730.680.555.550.31
Operating Income-10.54-9.06-7.59-5.71-7.11-10.76-7.16-4.69-2.96-7.88
Net Income-9.36-8.90-7.15-3.25-7.83-6.71-10.06-4.16-2.38-7.39
Shares Outstanding19.3813.186.143.482.612.061.551.111.101.01
Earnings Per Share-0.48-0.68-1.16-1.34-3.00-4.30-6.50-3.70-2.20-7.30
Operating Cash Flow-7.51-7.24-6.51-4.98-5.39-2.47-4.46-2.64-1.95-5.73
Capital Expenditures-0.02--0.03-0.01-0.02-0.05-0.02---0.01
Free Cash Flow-7.53-7.25-6.54-4.99-5.41-2.52-4.47-2.64-1.95-5.74
Cash & Equivalents5.428.987.818.774.925.535.863.366.007.45
Total Debt0.13---0.29-----
Net Cash / Debt5.298.987.818.774.635.535.863.366.007.45
Assets7.7810.499.5510.277.396.958.274.718.229.27
Liabilities6.324.213.232.877.417.1110.041.151.431.91
Book Value1.466.286.327.40-0.02-0.15-1.773.556.797.36
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Soligenix, Inc.
Country United States
Employees 15
CEO Christopher J. Schaber

Stock Information

Ticker Symbol SNGX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SNGX
IPO Date June 15, 1987

Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.